Monday November 24, 5:00 am Eastern Time
Company Press Release
SOURCE: Frost and Sullivan
Frost & Sullivan: DNA Microchips: Current Exploration of Niche
Markets Will Produce Large Future Dividends
MOUNTAIN VIEW, Calif., Nov. 24 /PRNewswire/ -- There have been three revolutions in modern biology: the discovery of
DNA, genetic engineering, and the utilization of genes to cure disease. DNA microchips are fueling this third revolution by
providing an automated, high-throughput technology which allows scientists to map out genetic codes found in DNA, creating
a potentially multi-billion dollar market in the biopharmaceutical industry.
A Strategic Assessment of the DNA Microchip Market, strategic research by Frost & Sullivan (www.frost.com), examines
the end-user applications of this exciting new technology including genomics, clinical diagnostics, and disease management.
Currently, genomics, the understanding of the human genome for developing therapeutic products to treat disease, is the most
financially successful application for DNA microchips. But with the introduction of the Affymetrix' GeneChip for HIV
genotyping, it is obvious that applications for clinical diagnostics are not far behind.
''DNA microchips are experiencing growth in genomics, not only because of the interest fueled by the human genome project,
but by its ability to greatly accelerate drug discovery,'' said Enal Razvi Ph.D., Frost & Sullivan senior biotechnology analyst.
''However in four to five years, once they receive the necessary FDA approval, the clinical diagnostics market will explode as
doctors utilize these chips to test for a variety of life-threatening conditions at a much lesser cost than what's currently available
on the market.''
For all its potential, long-term financing has become an issue in this emerging market as investments do not provide immediate
financial rewards. The most secure way to receive financing has been through acquiring exclusive intellectual property and
developing strategic partnerships. Thus far stock market valuations have been based more on patents and alliances than on the
revenues companies generate.
A Strategic Assessment of the DNA Microchip Market profiles many of the current market competitors and those anticipated
to make a significant impact through 2001. Each competitor has been evaluated in terms of company history, competitive
strategy, strengths, limitations, collaborations, as well as revenues where appropriate.
Selected Participants in this market include Affymetrix, Orchid Biocomputer, Darwin Molecular Corporation, Sarnoff
Corporation, Gene Logic, GeneTrace Systems, Genometrix, Hyseq, Incyte Pharmaceuticals, Molecular Tool, Mosaic
Technologies, Nanogen, Perkin-Elmer Applied Biosystems Division, Pharmacia Biotech, Synteni, and Vysis. Related
Companies in this market include Affymax Research Institute, Argonne National Laboratory, Aurora Biosciences Corporation
[Nasdaq:ABSC - news], Beckman Instruments, Becton Dickinson, Caliper Technologies, Exelixis Pharmaceuticals, Genome
Therapeutics Corp. [Nasdaq:GENE - news], Hewlett-Packard Company [NYSE:HWP - news], Human Genome Sciences,
MicroFab Technologies, Millennium Pharmaceuticals, PerSeptive Biosystems, Sequana Therapeutics, Third Wave
Technologies, and Visible Genetics.
This medical industry research has integrated the proven Frost & Sullivan Market Engineering consulting philosophy into the
entire research process. Critical phases of this research included: identification of industry challenges, market engineering
measurements, strategic recommendations, planning and market monitoring. All of the vital elements of this system help the
market participants navigate successfully through the DNA microchip market.
Frost & Sullivan is an international marketing consulting company that monitors the medical industry for market trends, market
measurements, and strategies. The ongoing research is utilized to update a series of research publications such as #5066-53,
U.S. DNA Probe Markets, and to support industry participants with customized consulting needs. Free executive summaries
of all Frost & Sullivan reports are available to the press.
For more information in the United States, contact:
Keith Hammond
California
650-237-4384
650-903-0915 fax
khammond@frost.com
Or, visit the company's web site: frost.com
SOURCE: Frost and Sullivan
More Quotes
and News:
Aurora Biosciences Corp (Nasdaq:ABSC - news)
Genome Therapeutics Corp (Nasdaq:GENE - news)
Hewlett-Packard Co (NYSE:HWP - news)
Related News Categories: biotech, computer hardware, computer peripheral, computers, medical/pharmaceutical |
